Discovery and development of the anticancer agent salinosporamide A (NPI-0052)

The discovery of the anticancer agent salinosporamide A (NPI-0052) resulted from the exploration of new marine environments and a commitment to the potential of the ocean to yield new natural products for drug discovery and development. Driving the success of this process was the linkage of academic...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry Vol. 17; no. 6; pp. 2175 - 2180
Main Authors Fenical, William, Jensen, Paul R., Palladino, Michael A., Lam, Kin S., Lloyd, G. Kenneth, Potts, Barbara C.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 15.03.2009
Subjects
Antineoplastic Agents - chemistry
Drug Discovery
Drugs, Investigational
Lactones - chemistry
Marine actinomycetes
Molecular Structure
NPI-0052
Proteasome inhibitor
Pyrroles - chemistry
Salinosporamide A
Marine actinomycetes
NPI-0052
Salinosporamide A
Proteasome inhibitor
Online AccessGet full text

Cover

More Information
Summary:The discovery of the anticancer agent salinosporamide A (NPI-0052) resulted from the exploration of new marine environments and a commitment to the potential of the ocean to yield new natural products for drug discovery and development. Driving the success of this process was the linkage of academic research together with the ability and commitment of industry to undertake drug development and provide the resources and expertise to advance the entry of salinosporamide A (NPI-0052) into human clinical trials. This paper offers a chronicle of the important events that facilitated the rapid clinical development of this exciting molecule.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2008.10.075